Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney Disease
Status:
Recruiting
Trial end date:
2026-10-20
Target enrollment:
Participant gender:
Summary
The prevalence of diabetes mellitus is increasing worldwide, and its complications are one of
the leading causes of mortality from non-communicable diseases. Due to the high prevalence of
diabetes and because 30-40% of diabetic patients [both type 1 (T1DM) and type 2 (T2DM)
diabetes mellitus] develop kidney dysfunction, diabetic nephropathy (DN) is the main cause of
end-stage renal disease worldwide. The renin-angiotensin-aldosterone system (RAAS),
endothelin, and urotensin II are vasoactive hormones that have been extensively studied as
other mediators although their relation to diabetic nephropathy is still speculative.
Phase:
Phase 2
Details
Lead Sponsor:
Mostafa Bahaa
Collaborators:
Maryam Ali Ali El Sayed Rizk Clinical pharmacy Department- Tanta University Osama Mohamed Hassan Ibrahim , Prof Clinical pharmacy Department- Tanta University Sahar El-Haggar, Prof Clinical pharmacy Department- Tanta University